Af­ter strug­gling with its sole drug for years, Mar­i­nus rides pos­i­tive da­ta to a com­mer­cial­iza­tion deal in Eu­rope

Af­ter a se­ries of painful set­backs, Mar­i­nus had a re­birth of sorts last year when it of­fered a pos­i­tive late-stage pre­view of its sole drug, ganax­olone, in a ge­net­ic dis­or­der that caus­es ear­ly-on­set epilep­sy. Now, CEO Scott Braun­stein is rid­ing that suc­cess to an NDA sub­mis­sion and a col­lab­o­ra­tion with the Finnish phar­ma com­pa­ny Ori­on to com­mer­cial­ize the can­di­date in Eu­rope.

Ori­on is putting down around $30 mil­lion up­front (€25 mil­lion) and $115 mil­lion in biobucks (€97 mil­lion) for ex­clu­sive rights to mar­ket both the oral and IV for­mu­la­tions of ganax­olone in the EU, UK and Switzer­land for the treat­ment of CD­KL5 de­fi­cien­cy dis­or­der (CDD), tuber­ous scle­ro­sis com­plex (TSC) and re­frac­to­ry sta­tus epilep­ti­cus (RSE).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER